Last reviewed · How we verify
NCT06563713
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of STSP-0902 in Healthy Subjects
Phase 1 trial testing STSP-0902 injection in Oligozoospermia in 40 participants. Completed in 24 February 2025.
24 February 2025
Quick facts
| Lead sponsor | Staidson (Beijing) Biopharmaceuticals Co., Ltd |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 31 July 2024 |
| Primary completion | 24 February 2025 |
| Estimated completion | 24 February 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- STSP-0902 injection — full drug profile →
- Placebo
Conditions studied
- Oligozoospermia — all drugs for Oligozoospermia →
- Asthenozoospermia — all drugs for Asthenozoospermia →
Sponsor
Staidson (Beijing) Biopharmaceuticals Co., Ltd — full company profile →
Who can join
Adults 18 to 50, male only, with Oligozoospermia or Asthenozoospermia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase 1a, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of STSP-0902.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06563713
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Oligozoospermia
Currently open trials in the same condition.
- NCT07375238 — Effect of Daily Intake of Gazpacho on Semen Quality and Oxidative Stress · NA · recruiting
- NCT07345455 — Probiotics on Sperm Quality in Male Infertility Patients · NA · recruiting
- NCT05628987 — The Association of Gut Microbiota and Spermatogenic Dysfunction · recruiting
Other Staidson (Beijing) Biopharmaceuticals Co., Ltd trials
Trials by the same sponsor.
- NCT07168161 — BDB-001 Phase III Trial in ANCA-Associated Vasculitis · Phase 3 · recruiting
- NCT06597422 — A Study of STSP-0902 Ophthalmic Solution in Healthy Subjects · Phase 1 · completed
- NCT06289166 — Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor · Phase 2 · completed
- NCT06038916 — To Evaluate The Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome · Phase 1, PHASE2 · completed
- NCT06148389 — The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06563713 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Staidson (Beijing) Biopharmaceuticals Co., Ltd
- Last refreshed: 11 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06563713.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing